Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:AVGROTCMKTS:BSTGNASDAQ:OBLNNASDAQ:TMDI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.52+1.3%$1.43$0.59▼$2.31$190.46M1.21.40 million shs854,366 shsAVGRAvinger$3.85+4.1%$3.44$2.50▼$18.00$6.12M1.2645,830 shs12,431 shsBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/AOBLNObalon Therapeutics$0.18+6.0%$4.22$0.66▼$10.77$1.78M-1.237.68 million shs172,531 shsTMDITitan Medical$0.14-26.3%$0.23$0.13▼$1.20$15.67M2.364.83 million shs7.71 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics+1.33%+7.04%-15.56%+85.37%+151.45%AVGRAvinger+4.05%-1.79%+30.73%+32.30%-59.86%BSTGBiostage0.00%0.00%0.00%0.00%-25.83%OBLNObalon Therapeutics+5.89%+4.28%-2.20%-13.55%-92.12%TMDITitan Medical0.00%0.00%0.00%0.00%0.00%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.3964 of 5 stars3.51.00.00.02.81.70.0AVGRAvinger2.6288 of 5 stars3.55.00.00.01.90.80.6BSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$4.50196.05% UpsideAVGRAvinger3.00Buy$5.0029.87% UpsideBSTGBiostageN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest OBLN, ATOS, TMDI, AVGR, and BSTG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/21/2024AVGRAvingerHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AAVGRAvinger$7.65M0.80N/AN/A($4.53) per share-0.85BSTGBiostageN/AN/AN/AN/A($0.26) per shareN/AOBLNObalon Therapeutics$1.59M1.12N/AN/A$0.60 per share0.30TMDITitan Medical$20.09M0.78N/AN/A$0.32 per share0.44Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)AVGRAvinger-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)BSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/AOBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/ATMDITitan Medical-$14.86M-$0.19N/A∞N/AN/A-167.03%-112.15%N/ALatest OBLN, ATOS, TMDI, AVGR, and BSTG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/20/2024Q4 2023AVGRAvinger$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AAVGRAvingerN/AN/AN/AN/AN/ABSTGBiostageN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A17.6117.61AVGRAvingerN/A0.630.36BSTGBiostageN/A2.732.73OBLNObalon TherapeuticsN/A1.861.86TMDITitan MedicalN/A1.411.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%AVGRAvinger18.30%BSTGBiostageN/AOBLNObalon Therapeutics18.64%TMDITitan Medical3.55%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%AVGRAvinger11.40%BSTGBiostage15.30%OBLNObalon Therapeutics8.10%TMDITitan Medical0.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableAVGRAvinger681.59 million1.41 millionNot OptionableBSTGBiostage713.88 million11.76 millionNot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionableTMDITitan Medical49111.95 million111.93 millionNot OptionableOBLN, ATOS, TMDI, AVGR, and BSTG HeadlinesSourceHeadlineTMD:CA Titan Medical Inc.seekingalpha.com - April 21 at 9:46 AMTitan Medical Inc.: Titan Medical Reports Fiscal Year 2023 Resultsfinanznachrichten.de - April 1 at 8:49 AMTitan Medical signs deal to merge with Conavi Medicalmsn.com - March 21 at 4:35 AMTitan Medical Inc TMDIFmorningstar.com - February 27 at 7:19 PMPerifery appoints Titan Data Solutions as authorised distributoradvanced-television.com - February 13 at 8:31 AMTitan Medical Inc (TMD)investing.com - February 13 at 1:56 AMVantage Titan 3T MRI Scanner from Toshibanews-medical.net - January 11 at 8:10 AMAttack on Titan: Hajime Isayama Will Create New Titan Story in 2024comicbook.com - October 3 at 1:41 AMFive dead on Titan sub were 'true explorers' - OceanGatebbc.com - September 28 at 10:21 PMTMDIF Titan Medical Inc.seekingalpha.com - August 1 at 7:27 PMFalse claim Titan passenger was the vice chairman of the World Economic Forum | Fact checkusatoday.com - July 25 at 1:09 PMNew details emerge about discovery of Titan submersible debrisen.as.com - July 19 at 9:22 AMDestiny 2 best Titan build for PvE and PvPvideogamer.com - July 18 at 7:32 AMPresumed human remains found in Titan sub debrisbbc.co.uk - July 14 at 5:59 PMThe Titan submersible imploded, killing all 5 on boardasahi.com - July 9 at 10:09 AMDebris and 'Presumed Human Remains' Recovered From Titan Submersiblemsn.com - June 30 at 7:39 PMUS Coast Guard says 'presumed human remains' found in wreckage of Titan submersiblewbaltv.com - June 30 at 1:27 PMTitan Sub Tragedy: "Presumed Human Remains" and Mangled Debris Recovered From Atlantic Oceaneonline.com - June 29 at 9:37 AMPossible human remains recovered from Titan wreckage, Coast Guard saysmsn.com - June 28 at 11:36 PMTitan submersible tragedy could lead to lawsuits and regulatory changes, experts sayyahoo.com - June 24 at 12:27 PMWhat happens during a catastrophic implosion? Titan submersible occupants likely died instantlywinknews.com - June 24 at 1:01 AMThe science that put the Titan submersible at risk of implosionktbs.com - June 24 at 1:01 AMThe Titan submersible: What could have gone wrong?msn.com - June 21 at 2:23 PMReport: Banging sounds heard during Titan submersible search, according to internal memowlox.com - June 21 at 12:43 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.AvingerNASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.BiostageOTCMKTS:BSTGBiostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Obalon TherapeuticsNASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Titan MedicalNASDAQ:TMDITitan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.